Literature DB >> 16641470

In vitro activities of DX-619 and four comparator agents against 376 anaerobic bacterial isolates.

D Molitoris1, M-L Väisänen, M Bolaños, S M Finegold.   

Abstract

The activity of DX-619 was evaluated against 376 anaerobic isolates using the reference CLSI agar dilution method. Overall, 90% of the strains were susceptible to DX-619 at < or =1 microg/ml. It was more active than the other four compounds tested except for meropenem, which showed virtually identical overall activity.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641470      PMCID： PMC1472202          DOI： 10.1128/AAC.50.5.1887-1889.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.

Authors:  Kim L Credito; Michael R Jacobs; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  In vitro antibacterial activity of DX-619, a novel des-fluoro(6) quinolone.

Authors:  Katsuko Fujikawa; Megumi Chiba; Mayumi Tanaka; Kenichi Sato
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

3.  Antistaphylococcal activity of DX-619, a new des-F(6)-quinolone, compared to those of other agents.

Authors:  Tatiana Bogdanovich; Duygu Esel; Linda M Kelly; Bülent Bozdogan; Kim Credito; Gengrong Lin; Kathy Smith; Lois M Ednie; Dianne B Hoellman; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.

Authors:  David W Hecht; J R Osmolski
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  Comparative articular toxicity of garenoxacin, a novel quinolone antimicrobial agent, in juvenile beagle dogs.

Authors:  Akio Nagai; Miyono Miyazaki; Teiichi Morita; Shinichi Furubo; Kazuo Kizawa; Hiroyuki Fukumoto; Takahiro Sanzen; Hiroyoshi Hayakawa; Yasuhito Kawamura
Journal:  J Toxicol Sci       Date:  2002-08       Impact factor: 2.196

6.  Effects of the Des-F(6)-quinolone garenoxacin (BMS-284756), in comparison to those of ciprofloxacin and ofloxacin, on joint cartilage in immature rats.

Authors:  Eva Maria Kappel; Mehdi Shakibaei; Akintunde Bello; Ralf Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  In vitro activities of a new des-fluoro(6) quinolone, garenoxacin, against clinical anaerobic bacteria.

Authors:  A Liebetrau; A C Rodloff; J Behra-Miellet; L Dubreuil
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  Antimicrobial susceptibility testing of Bilophila wadsworthia by using triphenyltetrazolium chloride to facilitate endpoint determination.

Authors:  P Summanen; H M Wexler; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191
  8 in total
  4 in total

1.  Lack of effect of DX-619, a novel des-fluoro(6)-quinolone, on glomerular filtration rate measured by serum clearance of cold iohexol.

Authors:  Nenad Sarapa; Prachi Wickremasingha; Nanxiang Ge; Richard Weitzman; Merynda Fuellhart; Cindy Yen; Julia Lloyd-Parks
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Activity of DX-619 compared to other agents against viridans group streptococci, Streptococcus bovis, and Cardiobacterium hominis.

Authors:  Klaudia Kosowska-Shick; Kathy Smith; Tatiana Bogdanovich; Lois M Ednie; Ronald N Jones; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

3.  In vitro antianaerobic activity of DX-619, a new des-fluoro(6) quinolone.

Authors:  Kaori Tanaka; Hiroshige Mikamo; Ken'ichi Nakao; Kunitomo Watanabe
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

4.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections.

Authors:  Sally Ager; Kate Gould
Journal:  Infect Drug Resist       Date:  2012-06-25       Impact factor: 4.003
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.